Canopy Partners LLC Buys 428 Shares of Eli Lilly and Company $LLY

Key Points

• Canopy Partners LLC increased its stake in Eli Lilly and Company by 37.9% in the second quarter, acquiring an additional 428 shares, bringing its total holdings to 1,556 shares valued at approximately $1.2 million.
• Analysts have recently reduced their price targets for Eli Lilly, with Deutsche Bank lowering it from $1,010 to $900, while the stock has an average rating of "Moderate Buy" and a consensus price target of $938.94.
• Eli Lilly reported strong earnings for the second quarter, with an EPS of $6.31, exceeding estimates, and revenue of $15.56 billion, marking a year-over-year increase of 37.6%.

Canopy Partners LLC grew its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 37.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,556 shares of the company's stock after acquiring an additional 428 shares during the period. Canopy Partners LLC's holdings in Eli Lilly and Company were worth $1,213,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of LLY. Hobbs Wealth Management LLC boosted its holdings in Eli Lilly and Company by 0.8% in the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock worth $1,205,000 after buying an additional 12 shares during the period. Hixon Zuercher LLC lifted its stake in Eli Lilly and Company by 0.7% in the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock worth $1,477,000 after purchasing an additional 12 shares in the last quarter. O Brien Wealth Partners LLC raised its position in shares of Eli Lilly and Company by 25.5% during the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after buying an additional 12 shares in the last quarter. Ascent Capital Management LLC raised its position in shares of Eli Lilly and Company by 2.5% during the 1st quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock valued at $409,000 after buying an additional 12 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners raised its position in shares of Eli Lilly and Company by 2.7% during the 1st quarter. Tennessee Valley Asset Management Partners now owns 493 shares of the company's stock valued at $407,000 after buying an additional 13 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently commented on LLY shares. Deutsche Bank Aktiengesellschaft cut their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Guggenheim dropped their target price on shares of Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research note on Wednesday, August 13th. JPMorgan Chase & Co. dropped their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a research note on Tuesday, September 16th. Daiwa Capital Markets downgraded shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price for the company. in a research note on Sunday, August 17th. Finally, Berenberg Bank reiterated a "hold" rating and set a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $938.94.

Eli Lilly and Company Trading Down 0.1%

Shares of NYSE:LLY opened at $844.30 on Wednesday. The company's 50 day moving average is $736.97 and its two-hundred day moving average is $766.03. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $937.00. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The company has a market cap of $799.09 billion, a PE ratio of 55.18, a P/E/G ratio of 1.18 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company's revenue for the quarter was up 37.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Activity

In other Eli Lilly and Company news, Director Jamere Jackson bought 200 shares of the company's stock in a transaction on Friday, August 8th. The stock was purchased at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the acquisition, the director owned 9,402 shares of the company's stock, valued at $6,013,143.12. The trade was a 2.17% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director J Erik Fyrwald bought 1,565 shares of the company's stock in a transaction on Tuesday, August 12th. The shares were acquired at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the acquisition, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock worth $2,894,841 in the last three months. Company insiders own 0.14% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.